June 12 – 17, 2022
Scale-up of suspension mammalian or insect cells to large bioreactors is commonly done in industry. However, some developers choose to scale-out adherent systems to produce desired components, since adherent systems are more challenging and costly to scale-up than suspension systems. Serum is often required for adherent cell culture, which can introduce lot-to-lot variability to the production process, can be cost-prohibitive, and raises ethical concerns. Additionally, increased global demand for serum is threatening to cause supply chain issues, which can impact manufacturing at scale. A process which reduces the concentration of serum while eliminating the challenges of scale-up for adherent systems would be extremely desirable to the biopharmaceutical industry. We have conducted scale-up studies using adherent human diploid MRC-5 fibroblast cells cultured with microcarriers with our serum reduced medium (SRM). The Diploid SRM System, is a three-component product with base medium and two supplement formulations optimized for cell growth and virus production, respectively.
Please click Download on the upper right corner to see the full abstract.
Michael Bruno, Haaris Huzair, and Anna-Barbara Hachmann, "Evaluation of a low-serum medium for growth and virus production with MRC-5 cells cultured on Cytodex 1 microcarriers" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/76